The present invention is directed towards isolated antibodies that bind to GRP78 and TIP-1.

Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.

The present invention provides a method for activating a pro-drug in vivo comprising the steps of: (a) administering a pro-drag to a subject; (b) locating a target site which has been at least partially dosed with the pro-drug at a predetermined concentration; and (d) exposing the target site to X-ray radiation. The step of exposing the target site to X-ray radiation is characterized by providing a converging X-ray of a controllable waist, substantially uniform at the target site, sufficient to convert the pro-drug to an active drug, whilst the X-ray photon dosage at the target site is higher than the X-ray photon dosage at an adjacent non target site.

An electromagnetic radiation activated device comprises a property changing material and at least one functionalized fullerene that upon irradiation of the functionalized fullerenes with electromagnetic radiation of one or more frequencies a thermally activated chemical or physical transformation occurs in the property changing material. The thermal activated transformation of the property changing material is triggered by the heating or combustion of the functionalized fullerenes upon their irradiation. The device can include a chemical agent that is embedded in the property changing material and is released when the material is heated by the functionalized fullerenes upon irradiation.

The disclosure herein relates to novel cancer-associated antibodies that are used in the treatment and diagnosis of a cancer. The complete polypeptide and nucleic acid consensus sequences of the antibodies disclosed herein are reconstructed in silico.

The present disclosure relates to uses of an ERK5 inhibitor, e.g., ERK5-in-1, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

The present invention provides antibodies which bind to the Delta/Serrate/LAG-2 consensus sequence (DSL) domain of human Jagged 1 via novel epitopes comprising the residue E228, and inhibit the interaction between human Jagged 1 and its associated receptors. Said antibodies may be administered therapeutically in the treatment of tumors/cancer, preferably those associated with tumoral Jagged 1-mediated signalling and tumor microenvironmental processes in which Jagged 1 and/or Notch-mediated signalling has been implicated, including those comprising Jagged 1-mediated cross talk between the tumor and the tumor microenvironment. The present invention also provides pharmaceutical compositions comprising said antibodies, uses of said antibodies in therapy, hybridomas comprising and/or secreting said antibodies and cells or cell lines expressing said antibodies and humanized/deimmunized variants in recombinant form.

There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.

The subject disclosure relates to compounds and compositions including chemotherapy agents and/or radiation therapy with bipolar trans carotenoids, and the use of such compounds for the treatment of various cancers including pancreatic and brain cancers.